glp 1 afib HRS 2026: GLP-1 Receptor Agonists Reduce Atrial Fibrillation Risk Independently of Weight Loss GLP-1 Drugs Show Growing Promise

Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG , Washington MK, Willett C, Wood DE, Wright CD, Yang G

Synovitis in osteoarthritis: current understanding with therapeutic implications

Accessed 09 Dec 2015 Stephens FB, Wall BT, Marimuthu K, Shannon CE, Constantin-Teodosiu D, Macdonald IA, Greenhaff PL (2013) Skeletal muscle carnitine loading increases energy expenditure, modulates fuel metabolism gene networks and prevents body fat accumulation in humans

The growing attention to receptor pathways that operate independently of oral or gastrointestinal delivery systems highlights why intranasal GLP-1 agonists are becoming relevant tools in investigative settings

doi: 10.3389/fpsyt.2021.611070 50

For oral administration in mice, NR and NMN are first metabolized by the liver or GI tract into NAM, which can then be taken up by other tissues